William Guyer Sells 11,767 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider William Guyer sold 11,767 shares of the business’s stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $36.01, for a total transaction of $423,729.67. Following the sale, the insider owned 2,231 shares in the company, valued at $80,338.31. This represents a 84.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

William Guyer also recently made the following trade(s):

• On Wednesday, March 4th, William Guyer sold 8,233 shares of Corcept Therapeutics stock. The shares were sold at an average price of $35.99, for a total transaction of $296,305.67.
• On Tuesday, February 3rd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $40.87, for a total transaction of $817,400.00.
• On Tuesday, January 6th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $35.18, for a total transaction of $703,600.00.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $38.53 on Friday. The company’s fifty day moving average is $37.47 and its two-hundred day moving average is $61.00. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01. Corcept Therapeutics Incorporated has a 12-month low of $28.66 and a 12-month high of $117.33. The company has a market cap of $4.10 billion, a P/E ratio of 46.99 and a beta of 0.29.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The business had revenue of $202.13 million during the quarter, compared to analyst estimates of $254.94 million. During the same period last year, the business earned $0.26 EPS. The business’s quarterly revenue was up 11.1% on a year-over-year basis. Equities analysts expect that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CORT. Rockefeller Capital Management L.P. raised its stake in shares of Corcept Therapeutics by 438.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 65,797 shares of the biotechnology company’s stock worth $2,290,000 after purchasing an additional 53,574 shares in the last quarter. Corient Private Wealth LLC lifted its holdings in shares of Corcept Therapeutics by 9.3% during the 4th quarter. Corient Private Wealth LLC now owns 7,035 shares of the biotechnology company’s stock valued at $245,000 after buying an additional 600 shares during the last quarter. SHP Wealth Management bought a new stake in shares of Corcept Therapeutics in the 4th quarter valued at approximately $72,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Corcept Therapeutics in the 4th quarter valued at approximately $8,757,000. Finally, Virtu Financial LLC acquired a new position in Corcept Therapeutics in the fourth quarter worth approximately $456,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Analysts Set New Price Targets

CORT has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Wolfe Research raised shares of Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research report on Thursday. HC Wainwright decreased their price target on shares of Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday. Canaccord Genuity Group boosted their price objective on shares of Corcept Therapeutics from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Truist Financial upgraded shares of Corcept Therapeutics to a “strong-buy” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $77.67.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel — the regulatory win is the primary commercial catalyst and triggered the recent multi‑day rally due to survival benefit data and earlier‑than‑expected decision. FDA Approves (BusinessWire)
• Positive Sentiment: Analyst/firm support: multiple firms raised or reiterated positive views (Truist to “strong‑buy”, Canaccord price target increase reported, HC Wainwright kept a Buy rating), which supports upside potential as the market prices in Lifyorli’s commercial opportunity. Analyst Coverage (Benzinga)
• Positive Sentiment: Insider confidence signal: market commentary highlighted a mid‑March purchase by a director (~100,000 shares) that likely helped amplify bullish positioning ahead of the approval. Insider Buy Analysis (QuiverQuant)
• Neutral Sentiment: Market structure/volatility: trading was temporarily halted (LULD pause) and the name has posted very large intraday moves as investors re‑price the company; expect elevated volume and short‑term volatility. Market Reaction Coverage (Reuters)
• Negative Sentiment: Multiple securities‑class‑action firms have filed/issued alerts alleging misstatements tied to prior FDA issues and patent litigation — several firms are seeking lead plaintiffs and note an April 21, 2026 deadline; these suits create tangible legal and financial overhang. Hagens Berman Alert (GlobeNewswire)
• Negative Sentiment: Recent insider selling: Corcept disclosed a sale by William Guyer (11,767 shares on Mar 20), which may be viewed negatively by some investors despite offsetting director purchases. Insider Sale SEC Filing

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.